Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd (RCE.AX) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Recce Pharmaceuticals Ltd (RCE.AX), covering cash flow, earnings, and balance sheets.
Recce Pharmaceuticals Ltd (RCE.AX) Income Statement & Financial Overview
Review Recce Pharmaceuticals Ltd RCE.AX income statement with detailed quarterly and annual figures.
| Metric | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $6.95M | $0.00 | $2.38M | $4.37M |
| Cost of Revenue | $8.39M | $173485.00 | $193283.00 | $141870.00 |
| Gross Profit | -$1.44M | -$173485.00 | $2.19M | $4.22M |
| Gross Profit Ratio | -$0.21 | $0.00 | $0.92 | $0.97 |
| R&D Expenses | $8.30M | $0.00 | $4.72M | $3.09M |
| SG&A Expenses | $4.71M | $12.27M | $9.41M | $7.93M |
| Operating Expenses | $13.008M | $12.27M | $9.41M | $7.93M |
| Total Costs & Expenses | $21.40M | $12.44M | $9.61M | $8.07M |
| Interest Income | $0.00 | $148107.00 | $38896.00 | $27366.00 |
| Interest Expense | $0.00 | $572433.00 | $274419.00 | $177036.00 |
| Depreciation & Amortization | $86491.00 | $173485.00 | $193283.00 | $141870.00 |
| EBITDA | -$7.04M | -$12.08M | -$9.28M | -$7.85M |
| EBITDA Ratio | -$1.01 | $0.00 | -$3.89 | -$1.82 |
| Operating Income | -$14.45M | -$12.44M | -$9.61M | -$8.07M |
| Operating Income Ratio | -$2.08 | $0.00 | -$4.03 | -$1.85 |
| Other Income/Expenses (Net) | -$20780.00 | -$381210.00 | -$135280.00 | -$95656.00 |
| Income Before Tax | -$14.47M | -$12.82M | -$9.74M | -$8.17M |
| Income Before Tax Ratio | -$2.08 | $0.00 | -$4.09 | -$1.87 |
| Income Tax Expense | -$6.74M | -$2.62M | -$2.28M | -$4.31M |
| Net Income | -$7.74M | -$10.20M | -$7.46M | -$3.85M |
| Net Income Ratio | -$1.11 | $0.00 | -$3.13 | -$0.88 |
| EPS | -$0.03 | -$0.05 | -$0.04 | -$0.02 |
| Diluted EPS | -$0.03 | -$0.05 | -$0.04 | -$0.02 |
| Weighted Avg Shares Outstanding | $228.86M | $203.99M | $179.37M | $180.03M |
| Weighted Avg Shares Outstanding (Diluted) | $229.00M | $203.99M | $179.37M | $180.03M |
The company's financials show resilient growth, with revenue advancing from $4.37M in Q4 2023 to $6.95M in Q2 2025. Gross profit remained healthy with margins at -21% in Q2 2025 compared to 97% in Q4 2023. Operating income hit -$14.45M last quarter, sustaining a consistent -208% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$7.04M. Net income rose to -$7.74M, while earnings per share reached -$0.03. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan